ID | 57486 |
FullText URL | |
Author |
Kunisada, Yuki
Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Eikawa, Shingo
Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
Tomonobu, Nahoko
Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Domae, Shohei
Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Uehara, Takenori
Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hori, Shohei
Laboratory of Immunology and Microbiology, Graduate School of Pharmaceutical Sciences, The University of Tokyo
Furusawa, Yukihiro
Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science
Hase, Koji
Division of Biochemistry, Keio University Graduate School of Pharmaceutical Science
Sasaki, Akira
Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Udono, Heiichiro
Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
researchmap
|
Abstract | CD4+CD25+ regulatory T cells (Treg), an essential subset for preventing autoimmune diseases, is implicated as a negative regulator in anti-tumor immunity. We found that metformin (Met) reduced tumor-infiltrating Treg (Ti-Treg), particularly the terminally-differentiated CD103+KLRG1+ population, and also decreased effector molecules such as CTLA4 and IL-10. Met inhibits the differentiation of naïve CD4+ T cells into inducible Treg (iTreg) by reducing forkhead box P3 (Foxp3) protein, caused by mTORC1 activation that was determined by the elevation of phosphorylated S6 (pS6), a downstream molecule of mTORC1. Rapamycin and compound C, an inhibitor of AMP-activated protein kinase (AMPK) restored the iTreg generation, further indicating the involvement of mTORC1 and AMPK. The metabolic profile of iTreg, increased Glut1-expression, and reduced mitochondrial membrane-potential and ROS production of Ti-Treg aided in identifying enhanced glycolysis upon Met-treatment. The negative impact of Met on Ti-Treg may help generation of the sustained antitumor immunity.
|
Keywords | Glycolysis
Regulatory T cell (Treg)
Tumor immunity
Tumor microenvironment
mTOR
|
Published Date | 2017-10-16
|
Publication Title |
EBioMedicine
|
Volume | volume25
|
Publisher | Elsevier Science
|
Start Page | 154
|
End Page | 164
|
ISSN | 23523964
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
Copyright Holders | © 2017 The Authors.
|
File Version | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.1016/j.ebiom.2017.10.009
|
License | https://creativecommons.org/licenses/by-nc-nd/4.0/
|
Citation | Yuki Kunisada, Shingo Eikawa, Nahoko Tomonobu, Shohei Domae, Takenori Uehara, Shohei Hori, Yukihiro Furusawa, Koji Hase, Akira Sasaki, Heiichiro Udono, Attenuation of CD4+CD25+ Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug, EBioMedicine, Volume 25, 2017, Pages 154-164, ISSN 2352-3964, https://doi.org/10.1016/j.ebiom.2017.10.009.
|
Funder Name |
Ministry of Education, Culture, Sports, Science and Technology
|
助成番号 | 15653356
26116709
|